In a recent move, Novo Nordisk has transferred its experimental Parkinson’s disease cell therapy program to Cellular Intelligence, a biotech startup backed by Mark Zuckerberg. The deal marks a shift in focus for Novo, which had been developing a stem-cell-based treatment called STEM-PD before shutting down its cell-therapy unit last year. The transfer allows Cellular